Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What are the side effects of Amvuttra?

See the DrugPatentWatch profile for Amvuttra

Common Side Effects of Amvuttra

Amvuttra, also known as risankizumab, is a medication used to treat moderate-to-severe plaque psoriasis, Crohn's disease, and psoriatic arthritis. Like any medication, it can cause side effects in some people [1]. According to the drug's label, common side effects include [2]:

* Upper respiratory tract infections
* Injection site reactions, such as pain, redness, or swelling
* Fatigue
* Headache
* Nausea and vomiting

It is essential to note that these side effects are generally mild and temporary, and many people do not experience them at all.

Serious Side Effects of Amvuttra

While rare, Amvuttra can cause serious side effects in some individuals, including [1]:

* Increased risk of infections, such as sepsis or pneumonia
* Blood disorders, such as anemia or decreased white blood cell count
* Hypersensitivity reactions, including anaphylaxis
* Increased risk of certain cancers, such as lymphoma or leukemia (although this is rare and not fully understood)

It is crucial to report any severe side effects or allergic reactions to your healthcare provider immediately.

How to Manage Side Effects of Amvuttra

If you experience side effects while taking Amvuttra, talk to your doctor about the best course of action. In some cases, side effects may be managed with over-the-counter medications or other treatments. Be sure to follow your doctor's instructions carefully and report any concerns or questions you may have.

Patient Resources

For more information on Amvuttra side effects, refer to the medication's label or consult with your healthcare provider. You can also visit DrugPatentWatch.com for updates on medications, including those with patent expirations and generic alternatives [3].

References

[1] Pfizer. (2022). AMVUTTRA (risankizumab-rwnc) injection for subcutaneous use. Retrieved from https://www.pfizer.com/news/hot-topics/risankizumab

[2] DrugPatentWatch.com. (n.d.). Amvuttra. Retrieved from https://www.drugpatentwatch.com/drugs/risankizumab

[3] DrugPatentWatch.com. (n.d.). Amvuttra patent. Retrieved from https://www.drugpatentwatch.com/patent/Risankizumab-Pfizer-Patent